Acadian Asset Management
ACRV icon

Acadian Asset Management’s Acrivon Therapeutics ACRV Stock Holding History

Acadian Asset Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
845,973
+264,765
+46% +$462K ﹤0.01% 1108
2025
Q4 		$1.4M Buy
581,208
+489,204
+532% +$1.06M ﹤0.01% 1016
2025
Q3 		$165K Buy
+92,004
New +$129K ﹤0.01% 1424

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management's ACRV Position: Q1 2026 in Review

Acadian Asset Management increased its Acrivon Therapeutics (ACRV) stake by 46% in Q1 2026, buying an estimated $462K and bringing the position to 845,973 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Acadian Asset Management first reported a position in ACRV in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.4M in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Acadian Asset Management held 845,973 shares of Acrivon Therapeutics worth $1.18M as of Q1 2026.
  • Acadian Asset Management bought 264,765 Acrivon Therapeutics shares in Q1 2026, an estimated $462K.
  • Acrivon Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1108 holding.
  • Acadian Asset Management first reported a position in Acrivon Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Acadian Asset Management's Acrivon Therapeutics position peaked at $1.4M in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.